artesunate amivas
amivas ireland ltd - artesunate - malaria - antiprotozoals - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children.consideration should be given to official guidance on the appropriate use of antimalarial agents.
artesunate kit
amivas, inc - artesunate (unii: 60w3249t9m) (.alpha.-dihydroartemisinin - unii:x0uiv26abx) - artesunate for injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. treatment of severe malaria with artesunate for injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen [see dosage and administration (2.1)] . limitations of use artesunate for injection does not treat the hypnozoite liver stage forms of plasmodium and will therefore not prevent relapses of malaria due to plasmodium vivax or plasmodium ovale . concomitant therapy with an antimalarial agent such as an 8-aminoquinoline drug is necessary for the treatment of severe malaria due to p. vivax or p. ovale [see dosage and administration (2.1)] . known serious hypersensitivity to artesunate, such as anaphylaxis [see warnings and precautions (5.2) and adverse reactions (6.2)] . there are serious risks to the mother and fetus associated with untreated severe malaria during pregnancy; delaying treatment of severe malaria in pregnancy may result in ser
ramivasc 2.5 capsules, hard 2.5 mg
salama pharmaceuticals limited, tanzania - ramipril - capsules, hard - 2.5 mg
amivas tablet
amico laboratories ltd. - rosuvastatin - tablet - 5 mg
amivas 10 tablet
amico laboratories ltd. - rosuvastatin - tablet - 10 mg
galzin- zinc acetate capsule
teva pharmaceuticals usa, inc. - zinc acetate (unii: fm5526k07a) (zinc cation - unii:13s1s8sf37) - zinc cation 25 mg - zinc acetate therapy is indicated for maintenance treatment of patients with wilson’s disease who have been initially treated with a chelating agent (see precautions: monitoring patients). zinc acetate capsules are contraindicated in patients with known hypersensitivity to any of the components of the formulation.
leqvio solution
novartis pharmaceuticals canada inc - inclisiran (inclisiran sodium) - solution - 284mg - inclisiran (inclisiran sodium) 284mg
leqvio inclisiran 284 mg /1.5 ml solution for injection in pre-filled syringe
novartis pharmaceuticals australia pty ltd - inclisiran, quantity: 284 mg - injection, solution - excipient ingredients: sodium hydroxide; phosphoric acid; water for injections - leqvio is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (ldl-c) in adults with heterozygous familial hypercholesterolaemia, atherosclerotic cardiovascular disease, or at high risk of a cardiovascular event:,? in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,,? alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.
leqvio 284 mg
novartis israel ltd - inclisiran as sodium - solution for injection - inclisiran as sodium 189 mg/ml - inclisiran - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:• in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl c goals with the maximum tolerated dose of a statin, or• alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.
cgen plus d200 capsule
56 kamias road, west kamias, quezon city; importer: n/a; distributor: n/a - ascorbic acid , zinc, colecalciferol (vitamin d3) - capsule - 500 mg (equivalent to 562.50 mg sodium ascorbate)/10 562.5 mg (equivalent to 70 mg zinc gluconate)/200 iu